+49 30 46307-200


Pylopass™ Introduction

Pylopass™ is a proprietary strain of Lactobacillus reuteri which specifically coaggregates with Helicobacter pylori in the stomach to reduce the bacterial load. Pylopass™ is comprised of spray-dried L. reuteri cells and is stable in a wide range of applications.


Pylopass™ - How It Works

Pylopass™ - A Unique Mode of Action

Scientists in Germany succeeded in identifying the Pylopass™ strain of L. reuteri after a detailed, multi-year screening process. It was selected for its anti-H. pylori characteristics from a culture collection of 8000 different food grade strains. Through a specific mechanism, Pylopass™ forms coaggregates with H. pylori to decrease the overall load in the stomach. The surface structures on Pylopass™ contain adhesion molecules that recognize and adhere to surface receptors on H. pylori. After coaggregation in the stomach has occurred, the entire coaggregate is excreted from the body through the digestive tract. Pylopass™ specifically binds to H. pylori and does not alter the microflora of the gut.

Watch this video to learn more about how Pylopass™ works

Advantages Over Probiotics

  • Product Stability - Unlike probiotics, Pylopass™ consists of inactivated cells which can withstand environmental fluctuations. For shipment and storage, Pylopass™ does not require temperature controls.
  • Specificity for H. pylori - While probiotics cater to general gut health, Pylopass™ specifically binds H. pylori in the stomach. Because of the specific nature of its activits in the gut, Pylopass™ does not bind or otherwise disturb the overall normal gut microbial balance.
  • Stability in Gastric Conditions - In contrast to probiotics, Pylopass™ employs a mechanism which is not dependent on binding sites or survival in the gastric environment. Probiotics can be beneficial because they may replace harmful bacteria in the gastrointestinal tract. However it is uncertain whether such living probiotic strains can withstand the acidic environment in the stomach. This concern is not a challenge for Pylopass™ as the coaggregation depends only on the binding of surface structures between Pylopass™ and H. pylori.

Advantages Over Other H. Pylori Reduction Methods

  • Good Tolerability - Other methods to reduce H. pylori load are generally non-specific and have numerous side effects such as diarrhea and taste disturbances. On the contrary, there are no known side effects related to Pylopass™ ingestion and administration.
  • Pylopass™ Ingestion Does Not Increase Antibiotic Resistance Risk - Research shows that the number of antibiotic resistant strains of H. pylori is increasing globally. In Asia, an estimated 37% of cases are resistant to metronidazole and 65% of cases are resistant to amoxicillin in Africa. Ramakrishna has argued against the case of eradication, as treatment with antibiotics may prove ineffective, due to high frequencies of antibiotic resistant strains. Pylopass™ offers an alternative management modality that does not contribute to the problem of antibiotic resistance in reducing H. pylori load.

The UBT Test

Two human studies have shown that Pylopass™ can decrease H. pylori load, measured via the urea breath test. This effect continues to be seen even six months after the end of the two week supplementation period with Pylopass™. The urea breath test (UBT) is a non-invasive method of testing for H. pylori infection that has been cited as one of the most important non-invasive tests for H. pylori detection. In order to survive the acidic environment of the stomach, H. pylori produces a neutral environment by producing urease. In the presence of urease, urea is converted to carbon dioxide and ammonia. Ammonia has a higher pH and thus neutralizes stomach acid, thereby creating an environment conducive for the survival of H. pylori. In the UBT test, the patient ingests a small amount of 13C-labelled urea. In those who are infected with H. pylori, 13C-labelled carbon dioxide and ammonia are produced. The labeled carbon dioxide is absorbed into the blood stream and then can be detected by a breath sample.

Pylopass™ Quality and Safety

Quality and Safety at a Glance:

Qualified Presumption of Safety (QPS) status in the EU No antibiotic resistance Manufactured according to HACCP guidelines Vegetarian Non-GMO

Pylopass™ Production Process

Microbial fermentation is a one of ORGANOBALANCE's core competencies. Pylopass™ is produced via fermentation in a controlled production facility. Because the coaggregation activity is of utmost importance, Pylopass™ is produced by standardization to coaggregation levels. This differs from a traditional probiotic, which is fermented to obtain a certain cell count. This means that Pylopass™ products have been fermented to their peak aggregation abilities. After fermentation, the cells are harvested, suspended in a matrix and spray dried to obtain a free flowing powder.

Pylopass™ Support

As a raw ingredient manufacturer, we not only actively promote our ingredients on a business-to-business level, but we also support our customers in many ways.

Regulatory Support

Our regulatory experts collaborate with authorities and organizations globally to work towards a regulatory situation that is in favor of Pylopass™ products. We have years of experience with regulatory dossiers and a track record of successful regulatory initiatives.

Formulation Support

Due to the stable nature of Pylopass™, it can be used as a dietary supplement or in functional foods and beverages. Based on human studies, the recommended daily dose of Pylopass™ is 200mg, which can be divided into several servings per day. One gram of Pylopass™ contains approximately 1 trillion cells.

Scientific Support

ORGANOBALANCE collaborates with universities and research centers around the world to strengthen the scientific backing of Pylopass™. We maintain a database of published literature which is used by our technical experts to provide tailor-made, well researched answers on technical questions.